NewAmsterdam Pharma (NAP), a Naarden, the Netherlands-based clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, closed a $196M (€160M) Series A funding round.
Forbion, NAP’s founding investor, was joined by Morningside Ventures and Ascendant BioCapital as co-lead investors in the Series A financing. Also participating in this funding round were Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dementia Fund, Peter Thiel, Janus Henderson Investors, Medpace, GL Capital, JVC Investment Partners, and Presight Capital.
Led by Michael Davidson, MD, chief executive officer, and John Kastelein, MD, PhD, FESC, chief scientific officer, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. In April 2020, the company acquired Dezima Pharma from Amgen, including all rights for obicetrapib (formerly AMG 899, now TA-8995) a selective cholesteryl ester transfer protein (CETP) inhibitor which targets Apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-c) in the body.
The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor, is being developed for patients who are not well-controlled on statins. Two Phase 2b clinical trials for obicetrapib are underway with targeted completion in Q2 2021. NAP is looking to initiate Phase 3 clinical trials in Q4 2021.